MEI Pharma, Inc.

( )
MEIP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
VRXValeant Pharmaceuticals International, Inc. -1.73%22.1314.1%$130.22m
AMRNAmarin Corp. Plc 0.00%14.671.6%$102.66m
CTLTCatalent, Inc. -1.74%51.542.2%$74.70m
JAZZJazz Pharmaceuticals Plc 1.31%114.582.3%$68.55m
UTHRUnited Therapeutics Corp. 2.15%102.9614.3%$61.94m
GWPHGW Pharmaceuticals Plc -2.06%102.316.2%$58.16m
PRGOPerrigo Co. Plc -2.22%50.676.8%$54.33m
AXSMAxsome Therapeutics, Inc. -4.48%78.001.9%$50.19m
HZNPHorizon Therapeutics Plc 0.47%34.226.6%$47.88m
ZGNXZogenix, Inc. 5.87%25.089.4%$44.19m
RVMDRevolution Medicines, Inc. -2.77%31.270.0%$41.35m
ICPTIntercept Pharmaceuticals, Inc. 7.67%91.9416.9%$40.55m
ENDPEndo International Plc -1.95%5.528.8%$39.24m
MNKMallinckrodt Plc 6.23%4.2620.9%$38.63m
SAGESAGE Therapeutics, Inc. -9.63%47.008.6%$37.15m

Company Profile

MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.